Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1

5(62.5%)

Phase 2

3(37.5%)

8Total

Phase 1(5)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06746480Phase 2Recruiting

Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma

Role: lead

NCT06126510Phase 2Recruiting

Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

Role: lead

NCT04806464Phase 1Recruiting

Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer

Role: lead

NCT06124001Phase 1Not Yet Recruiting

Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

Role: lead

NCT06113744Phase 1Unknown

A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

Role: lead

NCT06113731Phase 2Unknown

A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

Role: lead

NCT06008925Phase 1Recruiting

Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

Role: lead

NCT04758897Phase 1Unknown

Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors

Role: lead

All 8 trials loaded